Cargando…
Influenza antivirals and animal models
Influenza A and B viruses are among the most prominent human respiratory pathogens. About 3–5 million severe cases of influenza are associated with 300 000–650 000 deaths per year globally. Antivirals effective at reducing morbidity and mortality are part of the first line of defense against influen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157400/ https://www.ncbi.nlm.nih.gov/pubmed/35451200 http://dx.doi.org/10.1002/2211-5463.13416 |
_version_ | 1784718628534353920 |
---|---|
author | Caceres, C. Joaquin Seibert, Brittany Cargnin Faccin, Flavio Cardenas‐Garcia, Stivalis Rajao, Daniela S. Perez, Daniel R. |
author_facet | Caceres, C. Joaquin Seibert, Brittany Cargnin Faccin, Flavio Cardenas‐Garcia, Stivalis Rajao, Daniela S. Perez, Daniel R. |
author_sort | Caceres, C. Joaquin |
collection | PubMed |
description | Influenza A and B viruses are among the most prominent human respiratory pathogens. About 3–5 million severe cases of influenza are associated with 300 000–650 000 deaths per year globally. Antivirals effective at reducing morbidity and mortality are part of the first line of defense against influenza. FDA‐approved antiviral drugs currently include adamantanes (rimantadine and amantadine), neuraminidase inhibitors (NAI; peramivir, zanamivir, and oseltamivir), and the PA endonuclease inhibitor (baloxavir). Mutations associated with antiviral resistance are common and highlight the need for further improvement and development of novel anti‐influenza drugs. A summary is provided for the current knowledge of the approved influenza antivirals and antivirals strategies under evaluation in clinical trials. Preclinical evaluations of novel compounds effective against influenza in different animal models are also discussed. |
format | Online Article Text |
id | pubmed-9157400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91574002022-06-04 Influenza antivirals and animal models Caceres, C. Joaquin Seibert, Brittany Cargnin Faccin, Flavio Cardenas‐Garcia, Stivalis Rajao, Daniela S. Perez, Daniel R. FEBS Open Bio Reviews Influenza A and B viruses are among the most prominent human respiratory pathogens. About 3–5 million severe cases of influenza are associated with 300 000–650 000 deaths per year globally. Antivirals effective at reducing morbidity and mortality are part of the first line of defense against influenza. FDA‐approved antiviral drugs currently include adamantanes (rimantadine and amantadine), neuraminidase inhibitors (NAI; peramivir, zanamivir, and oseltamivir), and the PA endonuclease inhibitor (baloxavir). Mutations associated with antiviral resistance are common and highlight the need for further improvement and development of novel anti‐influenza drugs. A summary is provided for the current knowledge of the approved influenza antivirals and antivirals strategies under evaluation in clinical trials. Preclinical evaluations of novel compounds effective against influenza in different animal models are also discussed. John Wiley and Sons Inc. 2022-04-27 /pmc/articles/PMC9157400/ /pubmed/35451200 http://dx.doi.org/10.1002/2211-5463.13416 Text en © 2022 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Caceres, C. Joaquin Seibert, Brittany Cargnin Faccin, Flavio Cardenas‐Garcia, Stivalis Rajao, Daniela S. Perez, Daniel R. Influenza antivirals and animal models |
title | Influenza antivirals and animal models |
title_full | Influenza antivirals and animal models |
title_fullStr | Influenza antivirals and animal models |
title_full_unstemmed | Influenza antivirals and animal models |
title_short | Influenza antivirals and animal models |
title_sort | influenza antivirals and animal models |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157400/ https://www.ncbi.nlm.nih.gov/pubmed/35451200 http://dx.doi.org/10.1002/2211-5463.13416 |
work_keys_str_mv | AT cacerescjoaquin influenzaantiviralsandanimalmodels AT seibertbrittany influenzaantiviralsandanimalmodels AT cargninfaccinflavio influenzaantiviralsandanimalmodels AT cardenasgarciastivalis influenzaantiviralsandanimalmodels AT rajaodanielas influenzaantiviralsandanimalmodels AT perezdanielr influenzaantiviralsandanimalmodels |